Citations

Clear

4847 citation(s) found for "Tu, Eric".

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
Fajgenbaum, David C. , Bagg, Adam , Frank, Dale , Wu, David , Srkalović, Gordan , Simpson, David , Liu, Amy , Menke, David M. , Lechowicz, Mary Jo , Wong, Raymond , Pierson, Sheila K. , Paessler, Michele, Rossi, Jean‐François, Ide, Makoto , Ruth, Jason R., Croglio, M.P. , Suarez, Alexander , Chadburn, Amy , Colleoni, Gisele W. B. , Jayanthan, Raj , Nabel, Christopher S. , Kelleher, Dermot, Voorhees, Peter M. , Yoshizaki, Kazuyuki , Oksenhendler, Éric , Elenitoba‐Johnson, Kojo S.J. , Lim, Megan S. , Menke, David, Wong, Raymond S M , Uldrick, Thomas S. , Chandrakasan, Shanmuganathan , Rossi, Jean‐François , Krymskaya, Vera P. , Nasta, Sunita , Casper, Corey , Dispenzieri, Angela , Fosså, Alexander , Kurzrock, Razelle , Doǧan, Ahmet , Rhee, Frits van , Jaffe, Elaine S. , Fajgenbaum, David C , Ide, Makoto , Lim, Megan S

Mayo Clinic

Blood | January 13, 2017 | Volume: 129 | Issue: 12 | Pages: 1646-1657

10.1182/blood-2016-10-746933 | PMID 28087540 Get It

Key Points An international panel established the first ever diagnostic criteria for iMCD based on review of 244 clinical cases and 88 tissue samples. The criteria require multicentric lymphadenopathy with defined histopathology, ≥2 clinical/laboratory changes, and exclusion of iMCD mimics.
Novel Pathogenic Variant in TGFBR2 Confirmed by Molecular Modeling Is a Rare Cause of Loeys-Dietz Syndrome
Blackburn, Patrick R. , Cousin, Margot A. , Boczek, Nicole J. , Klee, Eric W. , Macmurdo, Colleen, Atwal, Paldeep S. , Zimmermann, Michael T. , Urrutia, Raul A, Atwal, Paldeep S , Urrutia, Raúl

Mayo Clinic

Case Reports in Genetics | January 9, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-4

10.1155/2017/7263780 | PMID 28163941 Get It

Loeys-Dietz syndrome (LDS) is a connective tissue disorder characterized by vascular findings of aneurysm and/or dissection of cerebral, thoracic, or abdominal arteries and skeletal findings. We report a case of a novel pathogenic variant in TGFBR2 and phenotype consistent with classic LDS. The proband was a 10-year-old presenting to the genetics clinic with an enlarged aortic root (Z-scores 5-6), pectus excavatum, and congenital contractures of the right 2nd and 3rd digit. Molecular testing of TGFBR2 was sent to a commercial laboratory and demonstrated a novel, likely pathogenic, variant in exon 4, c.1061T>C, p.(L354P). Molecular modeling reveals alteration of local protein structure as a result of this pathogenic variant. This pathogenic variant has not been previously reported in LDS and thus expands the pathogenic variant spectrum of this condition.
Identifying Brain Dysfunction Among Children With Acute Liver Failure—Can Spectral Electroencephalography Help?*
Payne, Eric T. , Kahoud, Robert J.

Mayo Clinic

Pediatric Critical Care Medicine | January 7, 2017 | Volume: 18 | Issue: 1 | Pages: 88-90

10.1097/pcc.0000000000001020 | PMID 28060158 Get It

Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, Eric, Trushina, Eugenia , Trushina, Eugenia

Mayo Clinic

Journal of Alzheimer’s Disease | January 6, 2017 | Volume: 57 | Issue: 4 | Pages: 1105-1121

10.3233/jad-161088 | PMID 28059794 Get It

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder without a cure. Most AD cases are sporadic where age represents the greatest risk factor. Lack of understanding of the disease mechanism hinders the development of efficacious therapeutic approaches. The loss of synapses in the affected brain regions correlates best with cognitive impairment in AD patients and has been considered as the early mechanism that precedes neuronal loss. Oxidative stress has been recognized as a contributing factor in aging and in the progression of multiple neurodegenerative diseases including AD. Increased production of reactive oxygen species (ROS) associated with age- and disease-dependent loss of mitochondrial function, altered metal homeostasis, and reduced antioxidant defense directly affect synaptic activity and neurotransmission in neurons leading to cognitive dysfunction. In addition, molecular targets affected by ROS include nuclear and mitochondrial DNA, lipids, proteins, calcium homeostasis, mitochondrial dynamics and function, cellular architecture, receptor trafficking and endocytosis, and energy homeostasis. Abnormal cellular metabolism in turn could affect the production and accumulation of amyloid-β (Aβ) and hyperphosphorylated Tau protein, which independently could exacerbate mitochondrial dysfunction and ROS production, thereby contributing to a vicious cycle. While mounting evidence implicates ROS in the AD etiology, clinical trials with antioxidant therapies have not produced consistent results. In this review, we will discuss the role of oxidative stress in synaptic dysfunction in AD, innovative therapeutic strategies evolved based on a better understanding of the complexity of molecular mechanisms of AD, and the dual role ROS play in health and disease.
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations
Ismail, Zahinoor , Agüera-Ortíz, Luis , Brodaty, Henry , Cieślak, Alicja , Gauthier, Serge , Geda, Yonas E. , Herrmann, Nathan , Kanji, Jamila, Mortby, Moyra E. , Onyike, Chiadi U. , Rosenberg, Paul B. , Smith, Gwenn S. , Sultzer, David L. , Lyketsos, Constantine G. , Cummings, Jeffrey L. , Fischer, Corinne Eleanor , Lanctôt, Krista L. , Miller, David S. , Smith, Eric Edward , Brodaty, Henry , Geda, Yonas E

Mayo Clinic

Journal of Alzheimer's Disease | January 6, 2017 | Volume: 56 | Issue: 3 | Pages: 929-938

10.3233/jad-160979 | PMID 28059789 Get It

Single-Anesthetic Versus Staged Bilateral Total Hip Arthroplasty
Watts, Chad D. , Wagner, Eric R. , Trousdale, Robert T. , Taunton, Michael J. , Houdek, Matthew T. , Wyles, Cody C. , Sierra, Rafael J. , Wagner, Eric R , Taunton, Michael J , Pagnano, Mark W

Mayo Clinic

Journal of Bone and Joint Surgery | January 6, 2017 | Volume: 99 | Issue: 1 | Pages: 48-54

10.2106/jbjs.15.01223 | PMID 28060233 Get It

Background: There is debate regarding the role of single-anesthetic versus staged bilateral total hip arthroplasty (THA) for patients with end-stage bilateral osteoarthritis. Studies have shown that single-anesthetic bilateral THA is associated with systemic complications, but there are limited data comparing patient outcomes in a matched setting of bilateral THA. Methods: We identified 94 patients (188 hips) who underwent single-anesthetic bilateral THA. Fifty-seven percent of the patients were male. Patients had a mean age of 52.2 years and body mass index of 27.1 kg/m 2 . They were matched 1:1 on the basis of sex, age (±1 year), and year of surgery (±3 years) to a cohort of patients undergoing staged bilateral THA. In the staged group, there was <1 year between procedures (range, 5 days to 10 months). Mean follow-up was 4 years for each group. Results: Patients in the single-anesthetic group experienced shorter total operating room time and length of stay. There was no difference (hazard ratio [HR] = 0.73, p = 0.50) in the overall revision-free survival in patients undergoing single-anesthetic or staged bilateral THA. The risks of reoperation (HR = 0.69, p = 0.40), complications (HR = 0.83, p = 0.48), and mortality (HR = 0.47, p = 0.10) were similar. Single-anesthetic bilateral THA reduced the total cost of care (by 27%, p = 0.0001). Conclusions: In this matched cohort analysis, single-anesthetic bilateral THA was not associated with an increased risk of revision, reoperation, or postoperative complications, while decreasing cost. In our experience, single-anesthetic bilateral THA is a safe procedure that, for certain patients, offers an excellent means to deal with bilateral hip osteoarthritis. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Hepatocytes Detoxify Atuna racemosa Extract
Buenz, Eric J.

Mayo Clinic

Experimental Biology and Medicine | January 5, 2017 | Volume: 231 | Issue: 11 | Pages: 1739-1743

10.1177/153537020623101111 | PMID 17138761 Get It

A number of traditional medicine plants are hepatotoxic. Thus, while the traditional uses of Atuna racemosa suggest little indication for toxicity, it is nonetheless important to examine the potential for this extract to target the liver. Using Jurkat T cells and HepG2 hepatocytes as a model, the potential hepatotoxicity of this extract was evaluated. The results of a conditioned media experiment suggest that A. racemosa extract would likely be detoxified by the liver. These results provide the necessary background to Initiate an in vivo toxicology investigation.
Serum alkylresorcinols as biomarkers of dietary gluten exposure in coeliac disease
Choung, Rok Seon , Marietta, Eric, Dyke, Carol T. Van, Ross, Alastair B. , Murray, Joseph A. , Choung, Rok Seon

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 4, 2017 | Volume: 45 | Issue: 5 | Pages: 643-652

10.1111/apt.13917 | PMID 28052442 Get It

SummaryBackgroundTherapy for coeliac disease (CD) mainly relies on following a gluten‐free diet (GFD); however, a serum marker for gluten intake has yet to be established.AimTo evaluate the utility of alkylresorcinol concentrations for detecting gluten intake in studies of human and mouse.MethodsAlkylresorcinol concentrations were compared among treated patients with coeliac disease (n = 34), untreated coeliac disease patients (n = 36) and controls (n = 33). Furthermore, seven additional coeliac disease patients whose serum samples were available at diagnosis and after GFD were evaluated. In mice studies, alkylresorcinol concentrations were compared in the serum of five mice fed a regular chow and 10 mice fed lifelong with a gluten‐free chow. In addition, the effect of adding gluten on changes of alkylresorcinol concentrations was also evaluated.ResultsTotal alkylresorcinol concentrations were significantly lower in treated with coeliac disease [median (IQR), 3 (2–8) nmol/L], compared to untreated patients [median (IQR), 32 (11–74) nmol/L; P < 0.0001] or healthy controls [median (IQR), 54 (23–112) nmol/L; P < 0.0001]. Moreover, alkylresorcinol concentrations in coeliac disease patients significantly decreased after introduction of a GFD (median, 34 nmol/L at diagnosis vs. 5 nmol/L after GFD, P = 0.02). In the mice, median (IQR) total alkylresorcinol concentrations in serum samples of mice fed lifelong with a gluten‐free chow was 1.8 (1.6–2.3) nmol/L, which was further significantly increased to 16 (11–22) nmol/L after 8 days of feeding with the gluten‐free chow that had gluten added to it. (P = 0.008).ConclusionSerum alkylresorcinol concentrations could be a useful marker for dietary gluten in coeliac disease.
“Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements
Palmowski, Yannick , Buttgereit, Thomas , Dejaco, Christian , Matteson, Eric L. , Voshaar, Marieke , Boers, Maarten , Buttgereit, Frank , Bijlsma, J. W. J. , Dejaco, Christian , Buttgereit, Frank

Mayo Clinic

Arthritis Care & Research | December 28, 2016 | Volume: 69 | Issue: 8 | Pages: 1134-1141

10.1002/acr.23185 | PMID 28029750 Get It

ObjectiveTo describe the perception of the current role of systemic glucocorticoids in the management of rheumatoid arthritis (RA) by examining their importance and the current level of evidence in recent guidelines, and to identify open questions to be addressed in future guidelines and research projects.MethodsWe conducted a systematic literature review using the databases Ovid Embase, PubMed Medline, and Cochrane Library for guidelines on the pharmacologic treatment of RA. Retrieved articles were evaluated regarding their quality using the Appraisal of Guidelines for Research and Evaluation II tool and scrutinized for all relevant information concerning the use of glucocorticoids.ResultsAll guidelines agree that glucocorticoids, especially if given at low doses and for a short duration, are an appropriate option in the treatment of RA. However, many recommendations remain vague, as reliable and detailed evidence is scarce. Important aspects of glucocorticoid therapy are partially or completely neglected, and the existing nomenclature is not used uniformly. Quality evaluation revealed flaws in many articles, concerning not only glucocorticoid‐specific recommendations but also guideline quality in general.ConclusionCurrent recommendations for use of glucocorticoids in the management of RA are suboptimal. More rigorous evaluation of doses, timing, and duration of their use is needed. Existing nomenclature on glucocorticoid therapy should be used uniformly.
Effect of Body Mass Index on Reoperation and Complications After Total Knee Arthroplasty
Wagner, Eric R. , Fruth, Kristin M. , Harmsen, William S. , Berry, Daniel J. , Kamath, Atul F. , Wagner, Eric R , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | December 24, 2016 | Volume: 98 | Issue: 24 | Pages: 2052-2060

10.2106/jbjs.16.00093 | PMID 28002368 Get It

Background: High body mass index (BMI) is associated with increased rates of complications after total knee arthroplasty. To date, to our knowledge, studies have examined risk as a dichotomous variable using specific BMI thresholds. The purpose of this investigation was to quantify implant survival and the risk of common complications after total knee arthroplasty using BMI as a continuous variable. Methods: Using prospectively collected data from our institutional total joint registry, we analyzed 22,289 consecutive knees, in 16,136 patients, treated with primary total knee arthroplasty from 1985 to 2012. The mean BMI of these patients at the time of the surgical procedure was 31.3 kg/m 2 (range, 11 to 69 kg/m 2 ). The Kaplan-Meier survival method was used to estimate survivorship, reoperations, and common complications, with associations of outcomes assessed using a Cox regression model. Results: Utilizing smoothing spline parameterization, we found that reoperation (p < 0.001) and implant revision or removal rates (p < 0.001) increased with increasing BMI after total knee arthroplasty. Increasing BMI also was associated with increased rates of wound infection (hazard ratio [HR], 1.07; p < 0.001) and deep infection (HR, 1.08; p < 0.001) per unit of BMI over 35 kg/m 2 . A BMI of 35 to 40 kg/m 2 was associated with a higher rate of implant revision for aseptic loosening (p < 0.001) and for polyethylene wear (p < 0.001) compared with a BMI of 18 to 24.99 kg/m 2 . There was no correlation between BMI and risk of venous thromboembolism, tibiofemoral instability, or need for knee manipulation. Conclusions: The rates of reoperation, implant revision or removal, and many common complications after total knee arthroplasty were strongly associated with BMI. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.